We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > endpoints

News List

Rituxan hits endpoints in late-stage skin disease trial pharmatimes
June 16, 2019
Roche has announced that its monoclonal antibody, Rituxan (rituximab), met all primary and secondary endpoints in the Phase III PEMPHIX study.
Zerbaxa Meets Primary Endpoints americanpharmaceuticalreview
September 12, 2018
Merck announced the pivotal Phase 3 clinical study evaluating the company’s antibiotic Zerbaxa (ceftolozane and tazobactam) at an investigational dose for the treatment of adult patients with either ventilated hospital-acquired bacterial pneumonia (HABP)
Ionis Announces Phase 3 NEURO-TTR Study of Inotersen Meets Primary Endpoints americanpharmaceuticalreview
May 16, 2017
Ionis Pharmaceuticals announced the Phase 3 NEURO-TTR study of inotersen (IONIS-TTRRx) in patients with familial amyloid polyneuropathy (FAP) met both primary endpoints.